Literature DB >> 19736900

Relationship between rate of infusion and reinforcing strength of oxycodone in humans.

Sandra D Comer1, Judy B Ashworth, Maria A Sullivan, Suzanne K Vosburg, Phillip A Saccone, Richard W Foltin.   

Abstract

The rate of drug delivery to the central nervous system is believed to be an important predictor of the reinforcing strength of a drug. However, only a few studies have directly examined the relationship between drug-taking behavior and rate of drug administration. The purpose of the present experiment was to determine whether manipulating the infusion rate of a fixed dose of opioid alters its reinforcing effectiveness in humans. Twelve heroin-dependent participants (11 male, one female) completed the 2.5-week inpatient study. During test days, participants received $20 and a dose of drug (0 or 40 mg oxycodone administered intravenously over 2, 15, 30, 60, or 90 minutes) in random order during a morning sample session. Participants then worked for the sampled dose and/or money amount during an afternoon choice session by making finger presses on a computer mouse. Under these conditions, 40 mg oxycodone served as a reinforcer only when it was delivered over 2 and 15 minutes. Subjective ratings of drug liking, good effect, and high were similar to the self-administration results. Peak plasma levels of oxycodone generally occurred at the end of each infusion, eg, 2 minutes for the 2-minute infusion duration. Extended-release opioid medications are commonly prescribed for treating pain. The present results provide empirical support for the development of extended-release opioid medications that are difficult to convert into more rapid-acting forms. Specifically, these "abuse-deterrent formulations" could prevent patients from tampering with their medications to enhance their euphoric and reinforcing effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19736900     DOI: 10.5055/jom.2009.0022

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  21 in total

1.  Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health.

Authors:  Perrine Roux; Claudia Tindall; Lionel Fugon; Janet Murray; Suzanne K Vosburg; Phillip Saccone; Maria A Sullivan; Jeanne M Manubay; Ziva D Cooper; Jermaine D Jones; Richard W Foltin; Sandra D Comer
Journal:  Addiction       Date:  2012-03       Impact factor: 6.526

2.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

3.  Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.

Authors:  William W Stoops; Paul E A Glaser; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2013-02-21       Impact factor: 4.530

4.  Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.

Authors:  Joshua A Lile; Shanna Babalonis; Cleeve Emurian; Catherine A Martin; Daniel P Wermeling; Thomas H Kelly
Journal:  J Clin Pharmacol       Date:  2010-07-29       Impact factor: 3.126

5.  Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.

Authors:  Katharine M Seip-Cammack; Brian Reed; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

6.  The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.

Authors:  Jermaine D Jones; Maria A Sullivan; Jeanne Manubay; Suzanne K Vosburg; Sandra D Comer
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

7.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

8.  Characterizing the relationship between increases in the cost of nicotine and decreases in nicotine content in adult male rats: implications for tobacco regulation.

Authors:  Tracy T Smith; Laura E Rupprecht; Alan F Sved; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-09-14       Impact factor: 4.530

9.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Douglas Y Shapiro; Sandra D Comer
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526

10.  Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.

Authors:  P Roux; L Fugon; J D Jones; S D Comer
Journal:  Am J Addict       Date:  2013-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.